astragaloside a has been researched along with Alloxan Diabetes in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 22 (66.67) | 24.3611 |
| 2020's | 10 (30.30) | 2.80 |
| Authors | Studies |
|---|---|
| Dongming, W; Dudu, WU; Kangrui, Y; Xiaomei, YE; Xiaowei, X; Zhi, C; Zhiqiang, YU | 1 |
| Cao, A; Fang, J; Guo, H; Shen, Q; Su, X; Wang, H; Wang, L; Wang, Y; Yao, X; Zhu, B | 1 |
| Wang, H; Wang, J; Zhang, H; Zhang, Z; Zhu, Y | 1 |
| Fan, H; Fan, Y; Li, P; Liu, Q; Zhou, Y; Zhu, B | 1 |
| Ji, T; Li, W; Wang, Z; Zhang, J; Zhang, Y; Zhu, Y | 1 |
| Liu, J; Qu, Q; Song, C; Sui, X; Sun, L; Wang, T; Zhang, Z | 1 |
| Ao, C; Chen, X; Gong, DY; Ma, YR; Zhou, XT; Zou, JJ | 1 |
| Chen, J; Fang, J; Huang, J; Wang, H; Wang, L; Wang, Y; Xing, L; Yao, X; Zhu, B | 1 |
| Hu, CQ; Li, YX; Liu, XZ; Ma, XF; Wang, BS; Zhang, CY | 1 |
| Han, D | 1 |
| Dong, X; Han, Y; Li, W; Li, Y; Su, Y; Zhang, J; Zhang, Y; Zhu, Y | 1 |
| Chen, F; Chen, X; Gong, P; Liu, N; Shi, F; Wang, L; Wang, S; Xiao, X; Yang, W | 1 |
| Cao, A; Guo, H; Peng, W; Wang, H; Wang, L; Wang, Y; Zang, Y; Zhang, X; Zhang, Y | 1 |
| Han, P; Li, S; Liu, X; Shao, M; Song, G; Sun, H; Wang, D; Wang, W; Wei, X; Wu, J; Xiong, G; Zeng, Y | 1 |
| Chai, XQ; He, KQ; Jiang, Y; Li, WP; Li, WZ; Yin, YY | 1 |
| Lei, X; Luo, FL; Ren, JG; Zhang, BD | 1 |
| Ge, N; Han, P; Li, S; Shao, M; Song, G; Sun, H; Wang, D; Wang, W; Yi, T; Yi, W; Yu, X | 1 |
| Leng, B; Lu, M; Tang, F; Wang, H; Zhang, Y; Zhang, Z | 1 |
| Gao, Y; Tian, N; Wang, T; Wang, X; Wu, B; Xu, J; Zhang, N; Zhu, Z | 1 |
| Chen, Q; Ji, T; Ju, Y; Li, W; Ma, K; Su, Y; Wang, Z | 1 |
| Leng, B; Nie, Q; Wang, H; Zhang, L; Zhu, L | 1 |
| Chen, J; Chen, Y; Gui, D; Guo, Y; Huang, J; Liu, X; Wang, N; Xiao, W | 1 |
| Chen, J; Chen, Y; Gui, D; He, D; Huang, J; Luo, Y | 1 |
| Chen, J; Chen, Y; Gui, D; He, D; Luo, Y; Wang, N | 1 |
| Qi, F; Song, Z; Teng, J; Yin, Y; Zhang, B | 1 |
| Ding, Y; Fang, Y; Huang, Q; Liu, Q; Liu, X; Liu, Y; Mao, P; Song, Q; Xie, P; Yuan, D; Yuan, S; Zhang, R; Zhao, C | 1 |
| Chen, D; Cheng, L; Pan, JH; Wang, ZS; Xie, XH; Xiong, F | 1 |
| Chen, LL; Guo, WW; Li, S; Li, YS; Lu, WS | 1 |
| Dai, L; Huang, P; Lan, F; Liu, T; Liu, Y; Lu, X; Luo, X; Yin, H; Yuan, B | 1 |
| Du, H; Han, P; Li, S; Shao, M; Song, G; Sun, H; Wang, W; Yi, T | 1 |
| Li, Q; Wang, Z; Wei, D; Wen, Z; Xiang, M; Zhang, F; Zhou, Y | 1 |
| Liu, ZQ; Lv, L; Pang, JX; Rao, JJ; Wang, GF; Wu, SG; Wu, SY; Xu, W; Zhang, JJ | 1 |
| Jiang, S; Qiu, J; Shen, J; Sun, S; Yin, H; Yin, X; Yu, J; Zhang, Y | 1 |
1 review(s) available for astragaloside a and Alloxan Diabetes
| Article | Year |
|---|---|
Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Saponins; Triterpenes | 2020 |
32 other study(ies) available for astragaloside a and Alloxan Diabetes
| Article | Year |
|---|---|
Astragaloside IV ameliorates insulin induced insulin resistance in HepG2 cells through reactive oxygen species mediated c-Jun N-terminal kinase pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Glucose; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Rats; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2023 |
Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; DNA-Binding Proteins; High Mobility Group Proteins; Kelch-Like ECH-Associated Protein 1; Mice; Mitochondria; Molecular Docking Simulation; NF-E2-Related Factor 2; Oxidative Stress; Podocytes; RNA, Small Interfering | 2023 |
Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Male; Muscle Proteins; Myocardium; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes | 2019 |
Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Protective Agents; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes | 2019 |
Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Diet, High-Fat; Fibrosis; Inflammation; Lipid Metabolism; Male; Myocardium; Rats; Saponins; Triterpenes | 2020 |
Astragaloside IV protects retinal pigment epithelial cells from apoptosis by upregulating miR‑128 expression in diabetic rats.
Topics: Animals; Apoptosis; Astragalus Plant; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Diabetes Mellitus, Experimental; Fas Ligand Protein; Female; Flow Cytometry; In Situ Nick-End Labeling; Male; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Saponins; Triterpenes | 2020 |
Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Forkhead Box Protein O1; Gene Expression Regulation; Glucose; Glucuronidase; Klotho Proteins; Male; Mice; Mice, Inbred C57BL; Podocytes; PPAR gamma; Protective Agents; Saponins; Signal Transduction; Triterpenes | 2021 |
Astragaloside IV Improves Angiogenesis and Promotes Wound Healing in Diabetic Rats
Topics: Animals; Cell Proliferation; Cells, Cultured; Cysteine Endopeptidases; Diabetes Mellitus, Experimental; Female; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; PPAR gamma; Proliferating Cell Nuclear Antigen; ras Proteins; Rats, Sprague-Dawley; Saponins; Signal Transduction; SUMO-1 Protein; Sumoylation; Triterpenes; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Vascular Endothelial Growth Factor Receptor-2; Wound Healing | 2021 |
Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Lipids; Liver; Oxidative Stress; Rats; Saponins; Triterpenes | 2021 |
Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Astragalus propinquus; Autophagy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose; Homeostasis; Insulin Resistance; Liver; Male; Oxidative Stress; Quality of Life; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; TOR Serine-Threonine Kinases; Triterpenes | 2021 |
Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway.
Topics: Adenylate Kinase; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Dietary Sucrose; Gastrointestinal Microbiome; Gene Expression Regulation; Glucose; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Saponins; Sirtuin 1; Specific Pathogen-Free Organisms; Triterpenes | 2021 |
Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Autophagy; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Male; Mice; Mice, Inbred C57BL; Podocytes; Protein Kinases; Saponins; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Triterpenes | 2017 |
Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network.
Topics: Albumins; Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Gene Regulatory Networks; Male; Mice; Mitochondria; Mitochondrial Dynamics; Saponins; Triterpenes | 2017 |
Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin‑induced diabetic rat model.
Topics: Acute Kidney Injury; Animals; Antioxidants; Collagen Type IV; Diabetes Mellitus, Experimental; Glutathione Peroxidase; Humans; Hyperinsulinism; Iatrogenic Disease; Oxidative Stress; Podocytes; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes | 2018 |
Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.
Topics: Albuminuria; Animals; Apoptosis; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; In Situ Nick-End Labeling; Male; Mice; MicroRNAs; Podocytes; Rats; Rats, Sprague-Dawley; Receptors, Tumor Necrosis Factor; Saponins; Signal Transduction; TNF Receptor-Associated Factor 5; Transfection; Triterpenes | 2018 |
Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Kidney; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Protective Agents; Saponins; Triterpenes | 2018 |
Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Toll-Like Receptor 4; Triterpenes | 2018 |
Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit.
Topics: Acetylation; Animals; Autophagy; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Saponins; Sirtuin 1; Structure-Activity Relationship; Transcription Factor RelA; Triterpenes | 2018 |
Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Down-Regulation; eIF-2 Kinase; Endoplasmic Reticulum Stress; Epithelial Cells; Male; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; Transcription Factor CHOP; Triterpenes | 2019 |
Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation.
Topics: Acetylcysteine; Animals; Aorta, Thoracic; Biomarkers; Calpain; Cysteine Proteinase Inhibitors; Diabetes Mellitus, Experimental; Dipeptides; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Hyperglycemia; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; Triterpenes; Vasodilation | 2019 |
Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
Topics: Albuminuria; Animals; Biomarkers; Chemokine CCL2; Collagen Type IV; Diabetes Mellitus, Experimental; Gene Expression Regulation; Inflammation; Intercellular Adhesion Molecule-1; Kidney Diseases; Male; NF-kappa B; Podocytes; Rats; Rats, Sprague-Dawley; RNA, Messenger; Saponins; Triterpenes; Tumor Necrosis Factor-alpha | 2013 |
Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Topics: Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Basement Membrane; Integrin alpha3; Integrin beta1; Male; Microscopy, Electron, Transmission; Podocytes; Protective Agents; Protein Serine-Threonine Kinases; Rats, Sprague-Dawley; RNA, Messenger; Saponins; Triterpenes | 2014 |
Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glucose; Heat-Shock Proteins; Male; Podocytes; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Saponins; Signal Transduction; Transcription Factor CHOP; Triterpenes | 2014 |
Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats.
Topics: Animals; Aorta, Abdominal; Coumaric Acids; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Hypoglycemic Agents; Male; Molecular Structure; Rats, Wistar; Saponins; Triterpenes | 2014 |
Protective effects of astragaloside IV on db/db mice with diabetic retinopathy.
Topics: Aldehyde Reductase; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Electroretinography; MAP Kinase Signaling System; Mice; NF-kappa B; Phosphorylation; Retinal Ganglion Cells; Saponins; Triterpenes | 2014 |
Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Male; Podocytes; Proteinuria; Random Allocation; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reference Values; Saponins; Streptozocin; Triterpenes; Urinalysis | 2015 |
Effects of Astragaloside IV on diabetic nephropathy in rats.
Topics: Actinin; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Humans; Integrin beta1; Kidney; Male; Protein Serine-Threonine Kinases; Rats; Saponins; Triterpenes | 2015 |
Astragaloside IV enhances diabetic wound healing involving upregulation of alternatively activated macrophages.
Topics: Animals; Anti-Inflammatory Agents; Astragalus propinquus; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Extracellular Matrix; Humans; Macrophage Activation; Macrophages; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Saponins; Skin; Triterpenes; Wound Healing | 2016 |
Astragaloside IV ameliorates renal injury in db/db mice.
Topics: Acetylglucosamine; Albuminuria; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glomerular Filtration Rate; Glycated Hemoglobin; Hypertrophy; Kidney; Lipocalin-2; Liver; Mice; Phosphorylation; Saponins; Signal Transduction; Transforming Growth Factor beta1; Triterpenes | 2016 |
Astragaloside Alleviates Hepatic Fibrosis Function via PAR2 Signaling Pathway in Diabetic Rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Gene Expression Regulation; Interleukin-1beta; Interleukin-6; Liver Cirrhosis; Male; Protein Kinase C-epsilon; Rats; Rats, Sprague-Dawley; Receptor, PAR-2; Saponins; Signal Transduction; Streptozocin; Transforming Growth Factor beta1; Triterpenes; Tumor Necrosis Factor-alpha | 2017 |
Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Drugs, Chinese Herbal; Glucose-6-Phosphatase; Glycogen Phosphorylase; Hypoglycemic Agents; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Saponins; Streptozocin; Triglycerides; Triterpenes | 2010 |
Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats.
Topics: Adenosine Triphosphatases; Aldehyde Reductase; Animals; Behavior, Animal; Blood Glucose; Body Weight; Cation Transport Proteins; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Erythrocytes; Glutathione Peroxidase; Glycated Hemoglobin; Glycation End Products, Advanced; Insulin; Models, Biological; Motor Activity; Pain Measurement; Rats; Rats, Sprague-Dawley; Saponins; Sural Nerve; Triterpenes | 2006 |